RAV12 + Gemcitabine
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer
Trial Timeline
Apr 15, 2008 → Mar 18, 2009
NCT ID
NCT00625586About RAV12 + Gemcitabine
RAV12 + Gemcitabine is a phase 2 stage product being developed by MacroGenics for Pancreatic Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00625586. Target conditions include Pancreatic Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00625586 | Phase 2 | Terminated |
Competing Products
20 competing products in Pancreatic Cancer